September 8, 2015 9:30am

The randomized, controlled three-arm trial enrolled 303 patients in the US and Canada. Top line results are expected in the first half of 2016. ADRO closed at $19.25. Look for some pricing movement. The road of share pricing has been “bumpy” for a little too long – 4/15/15, shares were priced at $42.00. BUY


Members only. Please login.